Drugs / Gelsectan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05045768 | Sep 2021 → Feb 2024 | irritable bowel syndrome | Evangelismos Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07000383 | Jun 2025 → Jul 2026 overdue | irritable bowel syndrome | University Medical Center Ho Chi Minh City (UMC) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gelsectan | “Gelsectan is a medical device containing xyloglucan, pea protein, and tannins, administered orally.” NCT07000383 ↗ |
| Modality | Other / unclassified | “Gelsectan is a medical device containing xyloglucan, pea protein, and tannins” NCT07000383 ↗ |